ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Data from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4

WALTHAM, Mass.--(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE^® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, have been selected for a late-breaking oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, Illinois.

"We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen. "Having demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to investigator's choice of single-agent chemotherapy, I believe ELAHERE has the potential to be practice changing in FRα-positive, platinum-resistant ovarian cancer."

ORAL PRESENTATION

Title: Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Initial Report of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Presenter: Dr. Kathleen Moore, Associate Director of Clinical Research and Director of the Oklahoma TSET/Sarah Cannon Phase I Program, Professor of the Section of Gynecologic Oncology at The University of Oklahoma and MIRASOL Principal Investigator
Session: Late-Breaking Abstract Session: Presentation and Discussion of LBA5507
Date: Sunday, June 4, 2023
Time: 7:30 am to 8:05 am CT / 8:30 am to 9:05 am ET

Late-breaking abstracts will be released at 7:00 am CT / 8:00 am ET on the day of the scientific presentation.

POSTER PRESENTATIONS
ImmunoGen will present two additional trial-in-progress posters at ASCO.

Title: GLORIOSA: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine with Bevacizumab vs. Bevacizumab as Maintenance in Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Presenter: Dr. David O'Malley, Professor, Director of Gynecologic Oncology at the Ohio State University and the James Cancer Center
Abstract: TPS5622
Poster Board: 312a

Title: A Phase 1b/2 Study of Pivekimab Sunirine in Combination with Venetoclax/Azacitidine or Magrolimab for Patients with CD123-Positive Acute Myeloid Leukemia
Presenter: Dr. Naval Daver, Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center
Abstract: TPS7073
Poster Board: 203a

Poster abstracts will be released on Thursday, May 25, 2023 at 4:00 pm CT / 5:00 pm ET.

Additional information can be found at www.asco.org.